A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B

PHASE2WithdrawnINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

June 30, 2009

Conditions
Von Willebrand Disease
Interventions
DRUG

ARC1779

"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.~Group NT3"

DRUG

ARC1779

"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.~Group T3"

DRUG

ARC1779

"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.~Group NT6"

DRUG

ARC1779

"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.~Group T6"

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Archemix Corp.

INDUSTRY

NCT00694785 - A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B | Biotech Hunter | Biotech Hunter